Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2021-05-21 AGM Information
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
AGM Information Classification · 98% confidence The document explicitly announces the 'Mise à disposition des documents préparatoires à l'Assemblée générale ordinaire du 11 juin 2021' (Making available of preparatory documents for the Ordinary General Meeting of June 11, 2021). It details the date, time, location (held behind closed doors), and voting procedures for the AGM. This content directly relates to the preparation and announcement of materials for a shareholder meeting, fitting the definition of AGM Information (AGM-R). Although it mentions documents are available, the primary focus is the announcement and logistics of the AGM itself, making AGM-R a stronger fit than RPA or RNS, which are usually for the release of financial reports.
2021-05-21 French
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 98% confidence The document explicitly states it announces 'revenue for the first quarter' and provides detailed financial tables for 'Q1 2021 revenue' and 'Financial structure at March 31, 2021'. This content structure—focusing on a specific, shorter reporting period (Q1) with key financial highlights and management commentary—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or a full Interim/Quarterly Report (IR), as it presents highlights rather than the full statutory statements typically found in an IR. The document is structured as a press release announcing these results, which aligns perfectly with the definition of an Earnings Release (ER). Q1 2021
2021-05-17 English
Information financière trimestrielle / Information financière du premier trimestre
Interim / Quarterly Report Classification · 95% confidence The document is a quarterly financial update from Genomic Vision for Q1 2021. It contains specific financial tables (revenue breakdown, cash position) and management commentary on business performance, market conditions, and future outlook. It is not a full interim report (which would be more extensive) but rather an earnings release/quarterly revenue announcement. It fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q1 2021
2021-05-17 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a press release announcing a business development: Genomic Vision completing the first milestone of a research agreement with Sanofi regarding genetic characterization. It details the progress, the technology used (Molecular Combing/FiberVision®), and includes quotes from the CEO. This type of announcement, focusing on strategic partnerships, research progress, and business milestones, is typically classified as a general business update or regulatory filing, but given the specific options, it most closely aligns with a general announcement that doesn't fit the strict definitions of an Earnings Release (ER), Interim Report (IR), or Capital Update (CAP). Since it is a formal announcement of a significant business event, and not a formal financial report, a proxy statement, or a director dealing report, the most appropriate general category for significant, non-financial-statement-focused corporate news that doesn't fit elsewhere is Regulatory Filings (RNS), which serves as a broad category for official company announcements not covered by more specific codes. It is not a transcript (CT), a management discussion (MDA), or a formal financial report (10-K, IR).
2021-05-13 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a press release from Genomic Vision announcing the successful completion of the first phase of a research agreement with Sanofi regarding genetic characterization of cell banks using their proprietary molecular combing technology. This announcement details a business development, a successful milestone achievement in a partnership, and provides commentary from management. It is not a full annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a transcript (CT). It is a specific business update that doesn't fit neatly into financing (CAP), M&A (TAR), or dividend (DIV) categories. Since it is a general announcement regarding business progress and partnership continuation, and does not fit the specific definitions for management changes (MANG), governance (CGR), or legal issues (LTR), it is best classified as a general Regulatory Filing (RNS) or potentially a type of Investor Presentation (IP) if it were a slide deck, but as a press release detailing operational progress, RNS serves as the most appropriate general announcement category when a more specific one is unavailable. Given the content is a positive operational update, RNS is the best fit as a general regulatory/corporate announcement.
2021-05-13 French
Rapports financiers et d'audit annuels / Modalités de mise à disposition du rapport financier annuel
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4485 characters) from Genomic Vision. The primary purpose of the text is to inform the public and the Autorité des marchés financiers (AMF) that the 'rapport financier annuel 2020' (Annual Financial Report 2020) has been made available. It also announces a delay for the Q1 revenue release. Because the document is an announcement *about* the availability of a report, and not the full report itself, it fits the definition of a Report Publication Announcement (RPA). The document explicitly states the report 'a été mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers' (has been made available to the public and filed with the AMF), which strongly suggests an RPA rather than the full 10-K or AR filing.
2021-05-06 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.